GlassScriptPhysician profile
Richard A Weiner
NPI 1851385579
$17,353.84
in general payments reported to CMS, 2019-2025
42 companies · $1,578 in 2025
The $1,578 reported for 2025 was more than what 96% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,207 · 2020: $699 · 2021: $2,572 · 2022: $4,537 · 2023: $2,530 · 2024: $2,232 · 2025: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,120 · Travel and Lodging: $922 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,119.83 |
| Travel and Lodging | $921.77 |
| Education | $298.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,314.28 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Vanta Adaptivestim |
| Relievant Medsystems, INC. | $2,537.98 | 2021-2023 | Intracept |
| Spinal Simplicity, LLC | $2,050.49 | 2021-2025 | Ha Minuteman G3-R |
| Boston Scientific Corporation | $1,168.61 | 2019-2024 | Wavewriter Alpha Prime 16, Intracept |
| Nevro Corp. | $1,056.67 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $902.81 | 2019-2025 | Belbuca, Xtampza |
| Vertos Medical, INC. | $792.54 | 2019-2024 | Mild Device Kit |
| Tersera Therapeutics LLC | $723.11 | 2019-2025 | Prialt |
| Painteq LLC | $580.94 | 2021-2024 | Painteq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $517.00 | 2019-2025 | Relistor |
| Spr Therapeutics, INC | $461.41 | 2019-2025 | Sprint Pns System |
| Scilex Pharmaceuticals INC. | $357.58 | 2019-2023 | Ztlido |
| Abbott Laboratories | $321.84 | 2019 | |
| Stimwave Technologies Incorporated | $284.86 | 2019-2021 | |
| Si-Bone, INC. | $279.36 | 2022-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $228.43 | 2019 | |
| Medtronic USA, INC. | $212.04 | 2019 | |
| Daiichi Sankyo INC. | $197.49 | 2019 | |
| Zyla Life Sciences, INC. | $156.09 | 2019-2020 | |
| Flowonix Medical Incorporated | $150.12 | 2019-2020 | |
| Nalu Medical, INC. | $135.88 | 2023-2025 | Nalu Neurostimulation System |
| Biohaven Pharmaceuticals, INC. | $117.95 | 2020-2021 | |
| Saluda Medical Americas, INC. | $104.81 | 2024-2025 | Evoke |
| Abbvie INC. | $94.96 | 2021-2023 | Qulipta |
| Horizon Therapeutics Plc | $58.99 | 2020-2022 | |
| West Therapeutics Development, LLC | $57.60 | 2019 | |
| Shionogi INC | $47.15 | 2019 | |
| Kaleo, INC. | $44.00 | 2019 | |
| Orexo US, INC. | $43.33 | 2019-2021 | |
| Indivior INC. | $38.85 | 2019-2023 | Sublocade |
| Avanos Medical | $36.35 | 2025 | Generator |
| Ibsa Pharma INC. | $35.20 | 2021 | |
| Protega Pharmaceutials INC | $32.57 | 2025 | Roxybond |
| Arbor Pharmaceuticals, INC. | $32.35 | 2019 | |
| Pfizer INC. | $28.36 | 2021 | |
| Averitas Pharma INC. | $27.99 | 2024 | Qutenza |
| Vision Quest Industries INC. | $27.62 | 2024 | Pro Estim Nmes Stimulator, Avid Ct2 Nmes/Ifc Stimulator |
| Eisai INC. | $24.34 | 2021 | |
| Piramal Critical Care | $24.16 | 2019 | |
| Amgen INC. | $21.57 | 2019 | |
| Redhill Biopharma INC. | $13.22 | 2021 | |
| Almatica Pharma LLC | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,921.92 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.